Physician profile
Pratik S Pradhan
NPI 1881652832
$51,057.81
in general payments reported to CMS, 2019-2025
23 companies · $45K in 2025
The $45K reported for 2025 was more than what 99% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2021: $1,033 · 2022: $174 · 2023: $3,111 · 2024: $1,835 · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Travel and Lodging: $4,939 · Food and Beverage: $3,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,462.50 |
| Travel and Lodging | $4,938.88 |
| Food and Beverage | $3,202.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $47,737.50 | 2019-2025 | |
| Stryker Corporation | $1,287.57 | 2019-2025 | Scopis Ent, Xpress Ent Dilation System, Audion Et Dilation System |
| Gyrus Acmi, INC. | $900.00 | 2021 | |
| Medtronic, INC. | $229.32 | 2023-2025 | Propel |
| Glaxosmithkline, LLC. | $193.32 | 2021-2025 | Nucala |
| Genzyme Corporation | $153.55 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $92.85 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $49.02 | 2022-2024 | |
| Neurent Medical Limited | $48.12 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Acclarent, INC | $46.13 | 2019-2023 | Acclarent Aera |
| Karl Storz Endoscopy-America | $45.43 | 2025 | |
| Optinose US, INC. | $39.13 | 2019-2024 | |
| Ethicon US, LLC | $33.70 | 2024 | Vistaseal |
| Hikma Pharmaceuticals USA | $31.97 | 2023-2024 | Ryaltris |
| Phadia US INC. | $27.79 | 2023 | Immunocap |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.18 | 2022 | |
| Alk-Abello, INC | $21.12 | 2022 | |
| Genentech USA, INC. | $20.96 | 2023 | Xolair |
| Pfizer INC. | $20.32 | 2022 | |
| Acera Surgical, INC. | $16.90 | 2025 | Restrata Wound Matrix |
| Welch Allyn | $15.23 | 2021 | |
| Merck Sharp & Dohme LLC | $14.43 | 2021 | |
| Smith+Nephew, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pratik Pradhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.